Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to here androgen deprivation.Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone.Direct and indirect costs were included in the model.The